{"title":"试验分析证实艾司卡胺鼻腔喷雾剂对TRD有疗效","authors":"","doi":"10.1002/pu.31276","DOIUrl":null,"url":null,"abstract":"<p>Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended-release quetiapine in patients with treatment-resistant depression (TRD). The additional analyses of the ESCAPE-TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in <i>The British Journal of Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"3"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Analysis of trial confirms efficacy of esketamine nasal spray in TRD\",\"authors\":\"\",\"doi\":\"10.1002/pu.31276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended-release quetiapine in patients with treatment-resistant depression (TRD). The additional analyses of the ESCAPE-TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in <i>The British Journal of Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 3\",\"pages\":\"3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31276\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31276","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Analysis of trial confirms efficacy of esketamine nasal spray in TRD
Several sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended-release quetiapine in patients with treatment-resistant depression (TRD). The additional analyses of the ESCAPE-TRD trial used multiple thresholds for remission and relapse. Study results were published online Dec. 2, 2024, in The British Journal of Psychiatry.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
